Amneal Pharmaceuticals (AMRX) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Amneal Reports Third Quarter 2021 Financial Results
November 3, 2021 6:00 AM EDTQ3 2021 Net Revenue of $529 million; GAAP Net Loss of $(4) million; Diluted Loss per Share of $(0.03)
Adjusted EBITDA (1) of $135 million; Adjusted Diluted EPS (1) of $0.21
Updating 2021 Full Year Financial Outlook, Including Raising Adjusted EBITDA and Adjusted EPS Guidance
Announces Acquisition of Puniska Healthcare to Significantly Expand Injectable Business
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (Amneal or the Company) announced its results today for the third quarter ended September 30, 2021.
Our solid third quarter results further validate... More
